Therefore, we analyzed soluble HMGB1 with regard to its relevance for prediction of therapy response and prognosis in advanced lung cancer patients and compared it with established lung cancer tumor markers CYFRA 21-1, CEA and NSE to investigate whether HMGB1 was a superior marker or whether it could add value to the information of other markers already used in routine diagnostics. This evidence concerns the gene CEACAM5 and lung cancer.